Determining Tumor Metabolism and Biochemical Mechanism of beta-glucan Action in

确定肿瘤代谢和 β-葡聚糖作用的生化机制

基本信息

  • 批准号:
    8744923
  • 负责人:
  • 金额:
    $ 26.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-19 至
  • 项目状态:
    未结题

项目摘要

Deaths from lung cancer are the highest of all cancers in the US. The complexity of lung cancer (LC) development suggests that a combination of approaches is needed to understand the mechanism of LC biology and tumor cell interactions with other cells such as immune cells within the tumor microenvironment. The concept of "cancer immunoediting" recognizes the complex and dynamic interactions between the tumor and host during tumor development, progression and metastasis. Although how the immune system plays a role in development and progression of human non-small cell lung carcinoma (NSCLC) is still elusive, innate macrophages are abundant in the NSCLC tumors. These macrophages are of immune suppressive M2 phenotype, promote tumor angiogenesis and metastasis and limit efficacy of chemotherapy for NSCLC. beta-Glucans, polysaccharides derived from various sources, can stimulate both innate and adaptive immune responses. Our preliminary data further demonstrate that beta-glucan treatment in vitro converts immune suppressive M2 macrophages into tumoricidal M1 phenotype and significantly decreases tumor-associated macrophage (TAM)-mediated immune suppression on CD4 and CDS T cells. Using the stable isotope resolved metabolomics (SIRM) approach, we show that glutamine (Gin) uptake and subsequent metabolism to glucose, glutathiones and lactate are enhanced when immune suppressive M2 macrophages are converted into an Ml phenotype. The central hvpothesis of this proposal is that differential human NSCLC subtypes may have distinct metabolic profiles and p-glucan treatment modulates TAM activity and metabolism, leading to the alterations of metabolic networks in NSCLC. We will use stable isotopic (13C, 15N) nutrient tracers in combination with the SIRM approach and metabolomics-edited transcriptomic analysis (META) to define key metabolic components of human NSCLC in vivo and investigate how beta-glucan treatment influences TAM phenotype, function, metabolism and subsequently tumor microenvironmental metabolic events. Three Specific Aims are proposed to determine the: 1 specific metabolic patterns of human NSCLC cells in xenografted tumors in severe combined immunodeficient (SCID) mice; 2) biochemical mechanisms of beta-glucan action in murine lung carcinoma models; 3) biochemical and phenotypic characteristics of human primary tumors implanted in N0D/SCID/IL-2gcNULL mice in response to beta-glucan administration. These investigations will advance our understanding of the biochemical underpinnings of tumor microenvironment nutrient utilization by NSCLC and how these processes are related to tumor immune evasion and immunomodulation.
肺癌是美国所有癌症中死亡率最高的。肺癌(LC)发展的复杂性 表明,需要结合各种方法来了解LC生物学机制 以及肿瘤细胞与肿瘤微环境中的其他细胞如免疫细胞的相互作用。的 “癌症免疫编辑”的概念认识到肿瘤和肿瘤细胞之间复杂和动态的相互作用, 在肿瘤发生、发展和转移过程中宿主。尽管免疫系统如何发挥作用 在人类非小细胞肺癌(NSCLC)的发展和进展中, 巨噬细胞在NSCLC肿瘤中丰富。这些巨噬细胞具有免疫抑制性M2 表型,促进肿瘤血管生成和转移,限制NSCLC的化疗效果。β-葡聚糖是一种来自不同来源的多糖,可以刺激先天性和适应性免疫反应。我们的初步数据进一步证明,β-葡聚糖体外处理可将免疫抑制性M2巨噬细胞转化为杀肿瘤的M1表型,并显著降低肿瘤相关巨噬细胞(TAM)介导的对CD 4和CDS T细胞的免疫抑制。使用稳定同位素分辨代谢组学(SIRM)方法,我们表明当免疫抑制性M2巨噬细胞转化为Ml表型时,谷氨酰胺(Gln)摄取和随后代谢为葡萄糖、谷胱甘肽和乳酸盐增强。该建议的中心假设是,不同的人类NSCLC亚型可能具有不同的代谢特征,β-葡聚糖治疗可调节TAM活性和代谢,导致NSCLC中代谢网络的改变。我们将使用稳定同位素(13 C,15 N)营养示踪剂结合SIRM方法和代谢组学编辑转录组学分析(Meta)来确定体内人类NSCLC的关键代谢组分,并研究β-葡聚糖治疗如何影响TAM表型,功能,代谢和随后的肿瘤微环境代谢事件。提出了三个特定目的来确定:1异种移植中人NSCLC细胞的特定代谢模式 严重联合免疫缺陷(SCID)小鼠的肿瘤; 2)β-葡聚糖的生化机制 在小鼠肺癌模型中的作用; 3)人原发性肺癌的生物化学和表型特征 植入N 0 D/SCID/IL-2gcNULL小鼠的肿瘤对β-葡聚糖给药的反应。这些调查 将促进我们对NSCLC肿瘤微环境营养利用的生化基础以及这些过程如何与肿瘤免疫逃避和免疫调节相关的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Teresa Whei-Mei Fan其他文献

Teresa Whei-Mei Fan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Teresa Whei-Mei Fan', 18)}}的其他基金

Mitochondrial Metabolic Reprogramming and DNA Damage in Arsenic Carcinogenesis
砷致癌过程中的线粒体代谢重编程和 DNA 损伤
  • 批准号:
    9090111
  • 财政年份:
    2015
  • 资助金额:
    $ 26.15万
  • 项目类别:
Mitochondrial Metabolic Reprogramming and DNA Damage in Arsenic Carcinogenesis
砷致癌过程中的线粒体代谢重编程和 DNA 损伤
  • 批准号:
    8927921
  • 财政年份:
    2015
  • 资助金额:
    $ 26.15万
  • 项目类别:
Integrated Chemoselective and Informatic Platform for Large-Scale Metabolomics
用于大规模代谢组学的集成化学选择性和信息平台
  • 批准号:
    8914844
  • 财政年份:
    2014
  • 资助金额:
    $ 26.15万
  • 项目类别:
Integrated Chemoselective and Informatic Platform for Large-Scale Metabolomics
用于大规模代谢组学的集成化学选择性和信息平台
  • 批准号:
    8916721
  • 财政年份:
    2014
  • 资助金额:
    $ 26.15万
  • 项目类别:
Administration, Bioinformatics and Biostatistics Core
管理、生物信息学和生物统计学核心
  • 批准号:
    8744925
  • 财政年份:
    2014
  • 资助金额:
    $ 26.15万
  • 项目类别:
Systems Biochemistry in Lung Cancer: Toward a Mechanistic Understanding of NSCLC
肺癌的系统生物化学:了解非小细胞肺癌的机制
  • 批准号:
    9025455
  • 财政年份:
    2014
  • 资助金额:
    $ 26.15万
  • 项目类别:
Microenvironmental Nutrient Availability and Immunomodulation in Lung Cancer Cel
肺癌细胞的微环境营养素利用率和免疫调节
  • 批准号:
    8744921
  • 财政年份:
    2014
  • 资助金额:
    $ 26.15万
  • 项目类别:
Determining Molecular Mechanisms of NSCLC and Response to beta-glucan
确定 NSCLC 的分子机制和对 β-葡聚糖的反应
  • 批准号:
    8744924
  • 财政年份:
    2014
  • 资助金额:
    $ 26.15万
  • 项目类别:
Stable Isotope Resolved Metabolomics Analytical Shared Core
稳定同位素解析代谢组学分析共享核心
  • 批准号:
    8744926
  • 财政年份:
    2014
  • 资助金额:
    $ 26.15万
  • 项目类别:
Integrated Chemoselective and Informatic Platform for Large-Scale Metabolomics
用于大规模代谢组学的集成化学选择性和信息平台
  • 批准号:
    8842359
  • 财政年份:
    2014
  • 资助金额:
    $ 26.15万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 26.15万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 26.15万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 26.15万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 26.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 26.15万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 26.15万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 26.15万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 26.15万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 26.15万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 26.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了